Group 1 - The core viewpoint of the article highlights the significant stock price increase of Beihai Kangcheng-B (01228), which has surged over 12% recently, bringing its year-to-date increase close to 20 times [1] - As of the report, the stock price reached 2.77 HKD with a trading volume of 50.08 million HKD [1] - On August 13, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will invest 100 million HKD to acquire shares in Beihai Kangcheng [1] Group 2 - The agreement also includes an exclusive commercialization service contract, enhancing strategic collaboration between Beihai Kangcheng and Baiyang Pharmaceutical [1] - Baiyang's subsidiary will gain promotional rights for specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1] - In 2025, the National Healthcare Security Administration will introduce a "Commercial Insurance Innovative Drug Directory," which has begun the application process as of July 11 [1] Group 3 - Beihai Kangcheng's three products, namely Geruneng (Injectable Vira Glycosidase β), Mairuibai (Chloramphenicol Oral Solution), and Hairuisi (Aidu Sulfate Esterase β Injection), passed the preliminary review on August 12, which is expected to accelerate market access [1] - The preliminary review list is considered significant for Beihai Kangcheng, as inclusion in the commercial insurance innovative drug directory would provide insurance support for the drugs, potentially reducing the economic burden on patients and improving product accessibility [1]
港股异动 北海康成-B(01228)再涨超12% 公司获百洋医药战略投资 旗下三款产品通过商保创新药目录初审